Xenon Pharmaceuticals Incis A Clinical Stage Biopharmaceutical Company Based In Burnabybritish Columbiafocused On Neurosciencethe Company Is Dedicated To Discovering And Developing Innovative Therapeutics For Neurological And Psychiatric Disordersoperating In Both Canada And The United States Xenon Has A Product Pipeline Centered Around Ion Channel Modulatorsparticularly Kv7 Potassium Channel Openersone Of Its Key Productsazetukalneris Currently In Phase 3 Trials For Epilepsy And Major Depressive Disorderwith Plans To Expand Trials To Bipolar Depressionthe Company Is Also Advancing Early Stage Programs Involving Kv7 And Nav1 7 Ion Channelswith Anticipated Ind Filings In 2025Additionallyxenon Collaborates With Neurocrine Biosciences To Develop A Nav1 2 Nav1 6 Inhibitorfurther Enhancing Its Research Capabilitiesxenon Pharmaceuticals Is Listed On Nasdaq Under The Ticker Symbol Xene And Is Preparing For Significant Milestones In The Coming Monthsincluding Data Readouts And Potential Product Launchesthe Company Is Led By President And Ceo Ian Mortimer And Actively Participates In The Life Sciences Community To Showcase Its Advancements
No conferences found for this company.
| Company Name | Xenon Pharmaceutical Pvt Ltd |
| Country |
Pakistan
|
| Address | 95 Km Sheikhupura Road Lahore |
| Telephone | Login to View |
| Login to View |
